9966 Stock Overview
A clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Alphamab Oncology Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.38 |
| 52 Week High | HK$13.46 |
| 52 Week Low | HK$2.00 |
| Beta | 0.28 |
| 11 Month Change | 76.61% |
| 3 Month Change | 94.67% |
| 1 Year Change | -46.78% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9966 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 60.4% | 18.3% | 8.7% |
| 1Y | -46.8% | 1.9% | 19.7% |
Return vs Industry: 9966 underperformed the Hong Kong Biotechs industry which returned 1.9% over the past year.
Return vs Market: 9966 underperformed the Hong Kong Market which returned 19.7% over the past year.
Price Volatility
| 9966 volatility | |
|---|---|
| 9966 Average Weekly Movement | 17.0% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 9966's share price has been volatile over the past 3 months.
Volatility Over Time: 9966's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 429 | Ting Xu | www.alphamabonc.com |
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase III clinical trials for treatment of HER2-positive breast cancer; and phase I and II clinical trial treatment of heavily pre-treated HER2 cancers, as well as Phase II clinical trial to treat unreselectable or metastatic HER2-positive solid tumors. The company’s product pipeline also comprises KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for neoadjuvant/adjuvant treatment of non-small cell lung cancer and endometrial cancer; and KN019, a CTLA-4-based immunosuppressant fusion protein, for auto-immune diseases and oncology treatment-induced immune disorders.
Alphamab Oncology Fundamentals Summary
| 9966 fundamental statistics | |
|---|---|
| Market cap | HK$4.22b |
| Earnings (TTM) | -HK$237.87m |
| Revenue (TTM) | HK$282.26m |
15.0x
P/S Ratio-17.7x
P/E RatioIs 9966 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9966 income statement (TTM) | |
|---|---|
| Revenue | CN¥255.87m |
| Cost of Revenue | CN¥52.88m |
| Gross Profit | CN¥202.99m |
| Other Expenses | CN¥418.62m |
| Earnings | -CN¥215.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 79.33% |
| Net Profit Margin | -84.27% |
| Debt/Equity Ratio | 19.6% |
How did 9966 perform over the long term?
See historical performance and comparison